| P50 | author | Kevin Ferreri | Q57317103 |
| P2093 | author name string | Michael Hensel | |
| | Fouad Kandeel | |
| | Ivan Todorov | |
| | Jeffrey Rawson | |
| | Mohamed I Husseiny | |
| | Indu Nair | |
| | Alexander Kaye | |
| P2860 | cites work | Chromogranin A is an autoantigen in type 1 diabetes | Q24605199 |
| | A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism | Q29614266 |
| | Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid | Q29615586 |
| | Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. | Q33361113 |
| | Quantitative assessment of β-cell apoptosis and cell composition of isolated, undisrupted human islets by laser scanning cytometry. | Q33653228 |
| | Rapid method for the construction of Salmonella enterica Serovar Typhimurium vaccine carrier strains | Q33716009 |
| | Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential | Q34082782 |
| | Autoantigens plus interleukin-10 suppress diabetes autoimmunity | Q34113929 |
| | Endocrine self and gut non-self intersect in the pancreatic lymph nodes | Q34202054 |
| | Mucosal immunity and vaccines | Q34409172 |
| | Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system | Q34471356 |
| | Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. | Q34496667 |
| | Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines | Q34531946 |
| | In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. | Q34691545 |
| | Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells | Q35180093 |
| | Central role for interleukin-2 in type 1 diabetes | Q35612414 |
| | Antigen-specific therapeutic approaches in Type 1 diabetes | Q35762883 |
| | Tolerance, not immunity, crucially depends on IL-2. | Q35877199 |
| | Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice | Q35913697 |
| | Manipulating cellular transport and immune responses: dynamic interactions between intracellular Salmonella enterica and its host cells. | Q36447552 |
| | Insulin as an autoantigen in NOD/human diabetes | Q36499414 |
| | Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial | Q36510973 |
| | Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial | Q36632019 |
| | Rational design of Salmonella recombinant vaccines | Q36948880 |
| | Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers | Q36988512 |
| | Dendritic cells in intestinal immune regulation. | Q37171796 |
| | The role of immunomodulation therapy in autoimmune diabetes | Q37408019 |
| | Therapy with GAD in diabetes | Q37408187 |
| | New technologies in using recombinant attenuated Salmonella vaccine vectors | Q37674803 |
| | Pre-existing immunity against vaccine vectors--friend or foe? | Q38061876 |
| | Progress in immune-based therapies for type 1 diabetes | Q38097920 |
| | Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses | Q40173820 |
| | Recombinant vaccines based on translocated effector proteins of Salmonella Pathogenicity Island 2. | Q40248092 |
| | Evaluation of an intracellular-activated promoter for the generation of live Salmonella recombinant vaccines | Q40444726 |
| | Vivotif--a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens. | Q40455781 |
| | Interpretation of the rapid intravenous glucose tolerance test in normal individuals and in mild diabetes mellitus | Q40991977 |
| | Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors | Q41956511 |
| | Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion | Q45864833 |
| | Evaluating the glucose tolerance test in mice | Q46350758 |
| | Evaluation of Salmonella live vaccines with chromosomal expression cassettes for translocated fusion proteins | Q47738556 |
| | Heterologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction | Q50063780 |
| | Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain | Q50135609 |
| | Impairment of Immunogenicity of Salmonella typhi Ty21a Due to Preexisting Cross-Reacting Intestinal Antibodies | Q50175544 |
| | Active immunity is seen as a reduction in the cell response to oral live vaccine | Q50187124 |
| | GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. | Q53291760 |
| | Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse | Q72415292 |
| | A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes | Q73306925 |
| | Islet-specific expression of IL-10 promotes diabetes in nonobese diabetic mice independent of Fas, perforin, TNF receptor-1, and TNF receptor-2 molecules | Q74183244 |
| | Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence | Q74733671 |
| | Oral tolerance | Q83849376 |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type-1 diabetes | Q124407 |
| | attenuated vaccine | Q1810913 |
| P304 | page(s) | 2300-2307 | |
| P577 | publication date | 2014-03-12 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | An oral vaccine for type 1 diabetes based on live attenuated Salmonella | |
| P478 | volume | 32 | |